Home Analyst Ratings JMP Securities reiterates Evelo Biosciences Inc. rating to Outperform and sets...

JMP Securities reiterates Evelo Biosciences Inc. [EVLO] rating to Outperform and sets new price target at $27

JMP Securities maintained its Evelo Biosciences Inc. [NASDAQ:EVLO]‎ rating to the equivalent of ‎Outperform but changed the price target ‎to $27, in a research note dated December 30, 2020. That ‎figure represents around a 139.57% ‎premium ‎from where the company’s shares closed on Tuesday. ‎Some ‎new analysts also started their coverage, with JMP Securities’s analysts assigning the shares to ‎‎”a Mkt ‎outperform” rating in a research note to investors issued in late December. Meanwhile, ‎Morgan ‎Stanley had lowered its rating on EVLO to “an Equal-weight” from the earlier “an Overweight”, ‎in a ‎research note produced for clients May 21, 2020. In addition, there was a downgrade from ‎Jefferies on ‎May 12, 2020. The rater changed EVLO from “a Buy” to “a Hold”.

Get the ‎hottest stocks to trade every day before the market opens 100% ‎free. Click here ‎now. 

Is Evelo Biosciences Inc. [NASDAQ:EVLO] a Good Buy Right Now?

It should be noted ‎that ‎EVLO technical indicators for short, intermediate as well as long term progress have placed an ‎overall ‎average of 100% as Buy. The average signal changed from 100% Buy in the last week and ‎compares ‎with 64% Buy in the past month. Data from Evelo Biosciences Inc.’s Trend Spotter indicated ‎that the ‎signals were Weakest. The stock current average is 0.71 million shares in the past 20 days and ‎the short ‎term average signal indicates a 100% Buy. In the last 50 days, the average trading volume was ‎‎0.36 ‎million shares while the medium term average advocated for 100% Buy. The average long-term ‎signal ‎stands at 100% Buy and the 100-day average volume stands at 0.26 million shares.‎‎


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


EVLO Price Performance

On Wall Street, Evelo Biosciences Inc. [NASDAQ:EVLO] ‎finished ‎Tuesday’s session down -8.22% at $11.27. The stock went up to $12.49 at the same session ‎while its ‎lowest single day price was $10.9701. In the last five days, it saw a rise of about 1.99%, ‎Evelo ‎Biosciences Inc. shares gained by almost 177.59% since the beginning of the year. However, the ‎share ‎price has dropped to as low as -9.84% below its one year high. On 12/28/20, the company ‎shares ‎recorded $12.50, the highest single-day price it has got to in the last 52-weeks and a 52-week ‎low was ‎seen on 03/16/20, the same year at $3.01. The company’s shares have inclined by 167.70% in ‎the past ‎year. The 50-day SMA achieved is $6.17 while the 200-day SMA is $4.91. Volume dropped to ‎‎0.26 ‎million from 0.69 million in the previous session.‎‎

EVLO Stock Support And Resistance Levels

On the 24-hour scale, the immediate backing ‎is ‎perceived around 10.66 level, and in case of violation of this particular level, it will cause more drop ‎to ‎‎10.06 level. On the upper level, 13.10 is still the key resistance. The stock may increase to ‎the ‎subsequent resistance at 12.18. The Relative Strength Index (RSI) pinned on the 14-day chart is ‎‎66.95, ‎implying a neutral technical stance while the MACD stands at 1.56, meaning price will increase in ‎the ‎next trading period. Percent R indicator moved to 17.08%, implying bullish price movement. ‎Stochastic ‎‎%K at 87.49% suggest selling the stock.‎‎

What is the short interest in Evelo Biosciences Inc.?

Short interest in the Evelo ‎Biosciences ‎Inc. stock has surged, increasing by 80000.0 shares to total 2.0 million shares on Dec 14, ‎‎2020. The ‎interest had seen shares on Nov 12, 2020 stand at 2.08 million, data from Yahoo Finance ‎shows. The ‎decrease of -4.0% suggests the stock saw some decreased bullish sentiment. The stock’s ‎days to cover ‎‎(short ratio) moved to while the shorted shares account for just 8.16% of the overall ‎float for the ‎stock.‎
‎‎

Get the hottest stocks to trade every day before the ‎market ‎opens 100% ‎free. Click here now. 

Evelo Biosciences Inc.’s Biggest Shareholders: Who Owns Evelo Biosciences ‎Inc. ‎‎[EVLO]?

Filings by Fidelity Management & Research Co showed that the firm now holds a ‎total of ‎‎5,000,985 shares or roughly 10.83% of the outstanding EVLO shares. This means their shares ‎have ‎increased by 449,766 from the 5,000,985 the investor reportedly held in its prior 13-F filing. With ‎the ‎conclusion of the purchase, Credit Suisse Securities updated stake is worth $12,873,145. Details in ‎the ‎latest 13F filings reveal that Credit Suisse Asset Management acquired their 35.03% stake valued ‎at ‎‎$8,245,998. During the last quarter, Credit Suisse Asset ‎Management raised 417,007 of its shares in ‎Evelo Biosciences Inc. while DNCA Finance SA bought ‎‎1,300,000 shares. The BVF Partners LP’s holdings ‎currently number 1,300,000 shares at $14651000.0. ‎According to the firm’s last 13F report, The ‎Vanguard Group, Inc. shares in the company at filing stood ‎at 848,050 shares, roughly $4,350,497.‎

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Flora Growth Corp. (FLGC) stock declines during premarket. Here’s what you should know?

Flora Growth Corp. (NASDAQ: FLGC) stock gained by 49.67% at last close whereas the FLGC stock price plunged by 18.36% in the pre-market trading...

Palatin Technologies Inc. (PTN) stock rises during pre-market trading. What has been happening lately?

Palatin Technologies Inc. (NASDAQ: PTN) stock declined by 1.16% the last close whereas the PTN stock price gains by 3.91% in the pre-market trading...

Smith Micro Develops Inc. (SMSI) stock soars during current market trading. Here’s to know why?

Smith Micro Develops Inc. (NASDAQ: SMSI) stock surged by 2.39% during the current market trading session. Smith Micro creates software that simplifies and improves...

Drive Shack Inc. (DS) stock soars during after-hour trading, followed by no recent update

Drive Shack Inc. (NASDAQ: DS) stock declined by 3.94% at last close while the DS stock-price surged by 7.38% in the after-hour session. Drive...

Oragenics Inc. (OGEN) stock gained during current market. What’s driving it high?

Oragenics Inc. (OGEN) stock gains by 54.33% during the current market trading session. Oragenics, is a research and development firm focused on combating infectious...

Tonix Pharmaceutics Holdings Inc. (TNXP) stock gains during current market. What’s driving it high?

Tonix Pharmaceuticals Holdings Inc. (TNXP) stock gains by 2.81% in the current market trading session. Tonix is a clinical-stage biopharmaceutical business dedicated on finding,...

Intec Pharma Inc. (NTEC) stock declines during current market after a massive upraise. What’s happening?

Intec Pharma Inc. (NASDAQ: NTEC) stock drops by 7.88% during the current market trading session. Intec Pharma is a clinical-stage biopharmaceutical firm specializing in...

Related News

Ocugen Inc. (NASDAQ:OCGN) stock plunged in the premarket trading session; here’s why

At last check Ocugen Inc. (OCGN) stock had plunged by-11.92% to $9.61 in premarket trading session. OCGN stock previously closed at $10.91 losing -12.79%....

KeyBanc reiterates Magna International [MGA] rating to Overweight and sets new price target at $86

KeyBanc maintained its Magna International rating to the equivalent of Overweight but changed the price target to $86.0 from $72, in a research...

Jefferies upgrades Medifast [MED] to Buy rating with a $265 price target

Jefferies took its Medifast rating to the equivalent of Buy from Hold, and the price target to $265.0 from $205, in a research...

American Eagle Outfitters [AEO] Upgraded to Outperform at RBC Capital

RBC Capital took its American Eagle Outfitters rating to the equivalent of Outperform from Sector Perform, and the price target to $30.0 from...

KeyBanc reiterates Nike [NKE] rating to Overweight and sets new price target at $180

KeyBanc maintained its Nike rating to the equivalent of Overweight but changed the price target to $180.0 from $174, in a research note...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam